Filing Flows › BioMarin Pharmaceutical (BMRN) › Q2 2026 › vs Q1 2026
BioMarin Pharmaceutical (BMRN) Q2 2026 vs Q1 2026 (quarter over quarter)
BioMarin Pharmaceutical's revenue rose $224M (+29%) from $766M in Q1 2026 to $990M in Q2 2026. Operating margin 11.2% against 16.9% (-5.7 pts).
BioMarin Pharmaceutical, Q2 2026: revenue $990M (+20% year over year), operating margin 11.2%, net earnings $44.8M, operating cash flow $168M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 11.2% | 16.9% | -5.7 pts |
| Net margin | 4.5% | 13.8% | -9.2 pts |
| Free cash flow margin | 14.1% | 26.1% | -12.0 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $990M | $766M | $224M | +29% |
| Operating profit | $111M | $130M | −$18.7M | -14% |
| Costs & expenses | $879M | $637M | $242M | +38% |
| Pre-tax earnings | $61.4M | $141M | −$79.8M | -57% |
| Other expense, net | $49.5M | −$11.6M | $61.1M | — |
| Cost of revenue | $203M | $195M | $7.8M | +4% |
| Research & development | $207M | $179M | $28.2M | +16% |
| SG&A | $396M | $258M | $137M | +53% |
| Other operating costs | $73.5M | $4.5M | $69.0M | 16× |
| Net earnings | $44.8M | $106M | −$60.8M | -58% |
| Income tax | $16.6M | $35.7M | −$19.1M | -53% |
| Operating cash sources | $218M | $165M | $52.7M | +32% |
| Depreciation & amortization | $97.6M | $16.4M | $81.2M | +495% |
| Share-based compensation | $75.7M | $43.5M | $32.2M | +74% |
| Working capital & other | $50.0M | −$55.3M | $105M | — |
| Operating cash flow | $168M | $221M | −$52.5M | -24% |
| Free cash flow (OCF − capex) | $139M | $200M | −$60.4M | -30% |
| Capital expenditures | $28.8M | $20.9M | $7.9M | +38% |
Questions
How much did BioMarin Pharmaceutical's revenue grow quarter over quarter in Q2 2026?
BioMarin Pharmaceutical's revenue rose $224M (+29%) from $766M in Q1 2026 to $990M in Q2 2026. Operating margin 11.2% against 16.9% (-5.7 pts).